The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...